Filtros de búsqueda

Lista de obras de

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

artículo científico publicado en 2013

A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer

artículo científico publicado en 2020

A Phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumors

artículo científico publicado en 2020

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer

artículo científico publicado en 2020

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

artículo científico publicado en 2016

A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases

artículo científico publicado en 2019

A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer

artículo científico publicado en 2013

A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.

scientific article published on 27 January 2014

A phase II trial of cabozantinib in hormone-receptor positive breast cancer with bone metastases

artículo científico publicado en 2020

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

scientific article published on 10 May 2019

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

scientific article published on 20 September 2020

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

scientific article published on 27 April 2020

Abstract P5-12-02: <i>PTEN</i> alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)

artículo científico publicado en 2019

Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)

artículo científico publicado en 2021

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer ⬇️

artículo científico publicado en 2015

An FDA Analysis of Survival Outcomes Comparing an Adjuvant Paclitaxel and Trastuzumab Trial to an External Control from Historical Clinical Trials

scientific article published on 28 August 2020

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

artículo científico publicado en 2018

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

artículo científico publicado en 2023

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

scientific article published on 01 March 2019

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

scientific article published on 24 April 2020

Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers

artículo científico publicado en 2020

CDK4/6 inhibition in breast cancer: current practice and future directions

scientific article published on 17 July 2018

CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

scientific article published on 28 September 2019

CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

artículo científico publicado en 2016

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

artículo científico publicado en 2015

Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer

scientific article published on 21 August 2020

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

artículo científico publicado en 2017

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

artículo científico publicado en 2015

Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond

artículo científico publicado en 2021

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

artículo científico publicado en 2016

Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC)

artículo científico publicado en 2020

Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim

artículo científico publicado en 2006

Database Selection and Heterogeneity-More Details, More Credibility-Reply

artículo científico publicado en 2018

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.

artículo científico publicado en 2018

DeepNeuro: an open-source deep learning toolbox for neuroimaging

artículo científico publicado en 2020

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

artículo científico publicado en 2020

Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial

artículo científico publicado en 2020

Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors.

artículo científico publicado en 2016

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

artículo científico publicado en 2016

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

artículo científico

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

scientific article published on 28 February 2019

Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review

artículo científico publicado en 2017

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

artículo científico publicado en 2018

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal

artículo científico publicado en 2014

Endocrine toxicity of cancer immunotherapy targeting immune checkpoints

article

Evidence to date: talazoparib in the treatment of breast cancer

artículo científico publicado en 2019

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer

artículo científico publicado en 2010

Follow-up care of patients with breast cancer

artículo científico publicado en 2007

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance

artículo científico publicado en 2019

Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the gene polymorphism

article

How we treat locally advanced HER2-positive breast cancer

scientific article published on 01 May 2019

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials

scientific article published on 15 November 2019

Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study

scientific article published on 24 April 2019

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

artículo científico publicado en 2014

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

artículo científico publicado en 2017

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

artículo científico publicado en 2018

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)

scientific article published on 19 April 2019

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

artículo científico publicado en 2019

Lymphopenia associated with adjuvant anthracycline/ taxane regimens

artículo científico publicado en 2008

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

artículo científico publicado en 2017

Mechanisms of trastuzumab resistance in breast cancer

artículo científico publicado en 2009

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

artículo científico publicado en 2021

NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE

artículo científico publicado en 2018

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction

artículo científico publicado en 2013

OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

artículo científico publicado en 2018

Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib

artículo científico publicado en 2017

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

scientific article published on 13 June 2019

Optimal treatment of early stage HER2-positive breast cancer

artículo científico publicado en 2018

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

artículo científico publicado en 2016

Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy

scientific article published on 15 September 2020

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

artículo científico publicado en 2013

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

artículo científico publicado en 2016

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases

artículo científico publicado en 2020

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

artículo científico publicado en 2013

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

artículo científico publicado en 2018

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

artículo científico publicado en 2015

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

artículo científico publicado en 2014

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients

artículo científico publicado en 2016

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

artículo científico publicado en 2018

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

artículo científico publicado en 2015

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

artículo científico publicado en 2013

Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

scientific article published on 04 September 2020

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

artículo científico publicado en 2016

Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.

artículo científico publicado en 2006

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors

artículo científico publicado en 2015

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer

artículo científico publicado en 2013

Prevalence and mutational determinants of high tumor mutation burden in breast cancer

artículo científico publicado en 2020

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

artículo científico publicado en 2020

Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche

scientific article published on 18 August 2021

Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche

artículo científico publicado en 2022

Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors

artículo científico publicado en 2019

Randomized trial of a clinic-based weight loss intervention in cancer survivors

artículo científico publicado en 2017

Randomized trial of a physical activity intervention in women with metastatic breast cancer

artículo científico publicado en 2016

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1

artículo científico publicado en 2020

Reply to A.K. Goel et al

scientific article published on 13 September 2019

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

scientific article published on 20 February 2020

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial

artículo científico publicado en 2019

Role of Immunotherapy in Triple-Negative Breast Cancer

artículo científico publicado en 2020

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

artículo científico publicado en 2015

Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial

scientific article published on 15 September 2020

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

artículo científico publicado en 2019

Sarcoidosis mimicking metastatic breast cancer

artículo científico publicado en 2007

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

artículo científico publicado en 2017

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

artículo científico publicado en 2019

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

artículo científico publicado en 2020

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

artículo científico publicado en 2020

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

scientific article published on 30 March 2020

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy

scientific article published on 06 May 2019

The Immunology of Hormone Receptor Positive Breast Cancer

publication published on 11 May 2021

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute

scientific article published on 22 September 2020

The evolving understanding of small HER2-positive breast cancers: matching management to outcomes

artículo científico publicado en 2015

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

artículo científico publicado en 2020

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial

scientific article published on 01 April 2019

The impact of high-dose glucocorticoids on the outcome of immune checkpoint inhibitor-related thyroid disorders

scientific article published on 14 May 2019

Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer

scientific article published on 04 February 2020

Utilization of tumor genomics in clinical practice: an international survey among ASCO members

artículo científico publicado en 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda